These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22030030)

  • 1. Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.
    Nankervis JL; Feil SC; Hancock NC; Zheng Z; Ng HL; Morton CJ; Holien JK; Ho PW; Frazzetto MM; Jennings IG; Manallack DT; Martin TJ; Thompson PE; Parker MW
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7089-93. PubMed ID: 22030030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
    Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3325-8. PubMed ID: 23602400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode.
    Kranz M; Wall M; Evans B; Miah A; Ballantine S; Delves C; Dombroski B; Gross J; Schneck J; Villa JP; Neu M; Somers DO
    Bioorg Med Chem; 2009 Jul; 17(14):5336-41. PubMed ID: 19525117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
    Gewald R; Grunwald C; Egerland U
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-C bond formation at C-2 of a quinoline ring: synthesis of 2-(1H-indol-3-yl)quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors.
    Kumar KS; Kiran Kumar S; Yogi Sreenivas B; Gorja DR; Kapavarapu R; Rambabu D; Rama Krishna G; Reddy CM; Basaveswara Rao MV; Parsa KV; Pal M
    Bioorg Med Chem; 2012 Apr; 20(7):2199-207. PubMed ID: 22386978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors.
    Chirgadze NY; Sall DJ; Briggs SL; Clawson DK; Zhang M; Smith GF; Schevitz RW
    Protein Sci; 2000 Jan; 9(1):29-36. PubMed ID: 10739244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.
    Xu RX; Rocque WJ; Lambert MH; Vanderwall DE; Luther MA; Nolte RT
    J Mol Biol; 2004 Mar; 337(2):355-65. PubMed ID: 15003452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
    Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
    Bioorg Med Chem; 2013 Nov; 21(22):7025-37. PubMed ID: 24094436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule allosteric modulators of phosphodiesterase 4.
    Gurney ME; Burgin AB; Magnusson OT; Stewart LJ
    Handb Exp Pharmacol; 2011; (204):167-92. PubMed ID: 21695640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.
    Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
    Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors.
    Wang H; Peng MS; Chen Y; Geng J; Robinson H; Houslay MD; Cai J; Ke H
    Biochem J; 2007 Dec; 408(2):193-201. PubMed ID: 17727341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
    Kato Y; Kawasaki M; Nigo T; Nakamura S; Fusano A; Teranishi Y; Ito MN; Sumiyoshi T
    Bioorg Med Chem; 2013 Sep; 21(18):5851-4. PubMed ID: 23910988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of a six-membered fused N-heterocyclic ring via a new 3-component reaction: synthesis of (pyrazolo)pyrimidines/pyridines.
    Kumar PM; Kumar KS; Mohakhud PK; Mukkanti K; Kapavarapu R; Parsa KV; Pal M
    Chem Commun (Camb); 2012 Jan; 48(3):431-3. PubMed ID: 22075973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a PDE4-Specific Pocket for the Design of Selective Inhibitors.
    Feng X; Wang H; Ye M; Xu XT; Xu Y; Yang W; Zhang HT; Song G; Ke H
    Biochemistry; 2018 Jul; 57(30):4518-4525. PubMed ID: 29975048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 1-alkynyl substituted 1,2-dihydroquinoline derivatives from nimesulide (and their 2-oxo analogues): a new strategy to identify inhibitors of PDE4B.
    Pal S; Durgadas S; Nallapati SB; Mukkanti K; Kapavarapu R; Meda CL; Parsa KV; Pal M
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6573-6. PubMed ID: 21920740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).
    Cameron RT; Coleman RG; Day JP; Yalla KC; Houslay MD; Adams DR; Shoichet BK; Baillie GS
    Biochem Pharmacol; 2013 May; 85(9):1297-305. PubMed ID: 23473803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of oral and inhaled PDE4 inhibitors.
    Ting PC; Lee JF; Kuang R; Cao J; Gu D; Huang Y; Liu Z; Aslanian RG; Feng KI; Prelusky D; Lamca J; House A; Phillips JE; Wang P; Wu P; Lundell D; Chapman RW; Celly CS
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5528-32. PubMed ID: 24018187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pd-mediated functionalization of polysubstituted pyrroles: their evaluation as potential inhibitors of PDE4.
    Bhaskar Kumar T; Sumanth Ch; Vaishaly S; Srinivasa Rao M; Chandra Sekhar KB; Meda CL; Kandale A; Rambabu D; Rama Krishna G; Malla Reddy C; Shiva Kumar K; Parsa KV; Pal M
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5639-47. PubMed ID: 22871579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.